The reviews analysis confirms that synthetic GLP-1 medications like semaglutide and tirzepatide, originally developed to control blood sugar, offer clinically validated protection against cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease (MASLD)-related outcomes, including improvements in steatosis and fibrosis-related endpoints

OptumRx PA criteria for Zepbound Standard OptumRx PA for Zepbound (obesity indication) typically requires: BMI 30 or higher, or BMI 27 with documented comorbidity (hypertension, type 2 diabetes, dyslipidemia, OSA) Participation in a structured weight-management program, typically 3 to 6 months of documented engagement Absence of contraindications (personal or family history of MTC, MEN 2) Attestation of medical necessity by the prescribing physician For step-therapy plans, prior trial of preferred GLP-1 alternative Initial approval is generally 6 months, with reauthorization requiring documented weight loss of 5% or more from baseline
Prefer speaking to an actual human
These innovative treatments can significantly impact weight management and overall well-being
Lean proteins also take longer to digest, which can help prevent quick spikes in blood sugar levels: In the short term, the rapid rise and fall of blood sugar levels can increase hunger and cravings, which may lead to overeating and contribute to weight gain
Will my provincial health plan cover Retatrutide